Immunitas Therapeutics (United States)
0 NOVEL BIOLOGY PATIENT IMPACTImmunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specializ
Basic Information
- Category: business
- Founded: 2019
- Website: https://www.immunitastx.com/
Documented Facts
- Email: info@immunitastx.com (No linked source recorded for this statement.)
- Founded: 2019 (No linked source recorded for this statement.)
- Website: https://www.immunitastx.com/ (No linked source recorded for this statement.)
- Country: United States (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Immunitas Therapeutics (United States).
- Canonical profile: https://brandsource.ai/brands/immunitas-therapeutics-united-states
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/immunitas-therapeutics-united-states/json-ld
- Citation profile API: https://brandsource.ai/api/brands/immunitas-therapeutics-united-states/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (90/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
0 NOVEL BIOLOGY PATIENT IMPACTImmunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specializ
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.